PAPERWORK REDUCTION ACT SUBMISSION SAN# 3970 Please read the instructions before completing this form. For additional forms or assistance in completing this form, contact your agency's Paperwork Clearance Officer. Send two copies of this form, the collection instrument to be reviewed, the Supporting Statement, and any additional documentation to: Office of Information and Regulatory Affairs, Office of Management and Budget, Docket Library, Room 10102, 725 17th Street NW Washington, DC 20503 1. Agency/ Subagency originating request U. S. Environmental Protection Agency Office or Air Radiation 2. OMB control number a. ______  ______ b.

None 2060____

3. Type of information collection ( check one) a.

New collection b. G Revision of a currently approved collection c. G Extension of a currently approved collection d. G Reinstatement, without change, of a previously approved collection for which approval has expired e. G Reinstatement, with change, of a previously approved collection for which approval has expired f. G Existing collection in use without an OMB control number For b f, note item A2 of Supporting Statement instructions 4. Type of review requested ( check one) a.

Regular b. G Emergency  Approval requested by: _____/_____/_____ c. G Delegated 5. Small entities Will this information collection have a significant economic impact on a substantial number of small entities?

G Yes

No 6. Requested expiration date a.

Three years from approval date b. G Other Specify: ____________/____________

7. Title National Emission Standards for Hazardous Air Pollutants for Cellulose Products Manufacturing ( Final Rule)

8. Agency form number( s) ICR 1974.02 9. Keywords Administrative Practice and Procedure, Air Pollution Control, Cellulose Products Manufacturing, Environmental Protection, Hazardous Substances, Intergovernmental Relations, Reporting and Recordkeeping Requirements.

10. Abstract Respondents are owners or operators of cellulose products manufacturing facilities. Respondents would submit notifications and rep and maintain records required by the General Provisions ( 40 CFR part 63, subpart A). Recordkeeping of parameters related to air pollution control technologies is required. The reports and records will be used to demonstrate compliance with the applicable emissi limits, operating limits, and work practice standards.

11. Affected public ( Mark primary with " P" and all others that apply with " X") a. Individuals or households d. Farms b. P Business or other for profit e. X Federal Government c. Not for profit institutions f. X State, Local or Tribal Government 12. Obligation to respond ( Mark primary with " P" and all others that apply with " X") a. Voluntary b. Required to obtain or retain benefits c. P Mandatory 13. Annual reporting and recordkeeping hour burden a. Number of respondents __________ 13 b. Total annual responses _________ 9 1. Percentage of these responses collected electronically _________ 20% c. Total annual hours requested _______ 1,436 d. Current OMB inventory ________ 0 e. Difference _______ 1,436 _ f. Explanation of difference 1. Program change _______ 1,436_ 2. Adjustment 0 14. Annual reporting and recordkeeping cost burden ( in thousands of dollars) a. Total annualized capital/ startup costs_________ 56.6 b. Total annual costs ( O& M) ___ ______ 0.2 c. Total annualized cost requested ____ ____ 56.8 d. Current OMB inventory ____ _____ 0 e. Difference _____ ___ 56.8 f. Explanation of difference 1. Program change 56.8 2. Adjustment _____ ___ 0 15. Purpose of information collection ( Mark primary with " P" and all others that apply with " X") a. ___ Application for benefits e. ___ Program planning or management b. ___ Program evaluation f. ___ Research c. ___ General purpose statistics g. P Regulatory or compliance d. ___ Audit 16. Frequency of recordkeeping or reporting ( check all that apply) a.

Recordkeeping b. G Third party disclosure c.

Reporting 1.

On occasion 2. G Weekly 3. G Monthly 4. G Quarterly 5.

Semi annually 6. G Annually 7. G Biennially 8. G Other ( describe)

17. Statistical methods Does this information collection employ statistical methods?

G Yes

No 18. Agency contact ( person who can best answer questions regarding the content of submission) Name: Bill Schrock, ESD/ OCG Phone: ( 919) 541 5032 OMB 83 I 10/ 95 19. Certification for Paperwork Reduction Act Submissions On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9.

NOTE: The text of 5 CFR 1320.9, and the related provisions of 5 CFR 1320.8( b)( 3), appear at the end of the instructions. The certification to be made with reference to those regulatory provisions as set forth in the instructions.

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

( a) It is necessary for the proper performance of agency functions; ( b) It avoids unnecessary duplication; ( c) It reduces burden on small entities; ( d) It uses plain, coherent, and unambiguous terminology that is understandable to respondents; ( e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices; ( f) It indicates the retention periods for recordkeeping requirements; ( g) In informs respondents of the information called for under 5 CFR 1320.8( b)( 3): ( i) Why the information is being collected; ( ii) Use of information; ( iii) Burden estimate; ( iv) Nature of response ( voluntary, required for a benefit, or mandatory); ( v) Nature and extent of confidentiality; and ( vi) Need to display currently valid OMB control number. ( h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected ( see note in Item 19 of the instructions); ( i) It uses effective and efficient statistical survey methodology; and ( j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item below and explain the reason in Item 18 of the Suppo Statement.

Signature of Program Office Official Date Signature of Senior Official or Designee Director, Collection Strategies Division Date OMB 83 I 10/ 95


[Federal Register Volume 76, Number 88 (Friday, May 6, 2011)]
[Notices]
[Pages 26305-26307]
[FR Doc No: 2011-11073]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0275]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Certification To Accompany Drug, Biological Product,
and Device Applications or Submissions (Form FDA 3674)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the requirements for certain
FDA applications or submissions to be accompanied by a certification,
Form FDA 3674, to ensure all applicable statutory requirements have
been met.

DATES: Submit either electronic or written comments on the collection
of information by July 5, 2011.

ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the Office
of Management and Budget (OMB) control number 0910-0616. Also include
the FDA docket number found in brackets in the heading of this
document.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., P150-400B,
Rockville, MD 20850,<PHONE_NUMBER><EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from OMB for each collection of
information they conduct or sponsor. ``Collection of information'' is
defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency
requests or requirements that members of the public submit reports,
keep records, or provide information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in the Federal Register concerning
each proposed collection of information, including each proposed
extension of an existing collection of information, before submitting
the collection to OMB for approval. To comply with this requirement,
FDA is publishing notice of the proposed extension of an existing
collection of information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed extension of
the collection of information is necessary for the proper performance
of FDA's functions, including whether the information will have
practical utility; (2) the accuracy of FDA's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Certification To Accompany Drug, Biological Product, and Device
Applications or Submissions (Form FDA 3674)--(OMB Control Number 0910-
0616)--Extension

    The information required under section 402(j)(5)(B) of the Public
Health Service Act (PHS Act) (42 U.S.C. 282(j)(5)(B)) is submitted in
the form of

a certification, Form FDA 3674, which accompanies applications and
submissions currently submitted to FDA and is already approved by OMB.
The OMB control numbers and expiration dates for submitting FDA 3674
under the following parts are: 21 CFR parts 312 and 314 (human drugs)
are 0910-0014, expiring August 31, 2011, and 0910-0001, expiring May
31, 2011; 21 CFR parts 312 and 601 (biological products) are 0910-0014
and 0910-0338, expiring December 31, 2013; 21 CFR parts 807 and 814
(devices) are 0910-0120, expiring December 31, 2013, and 0910-0231,
expiring December 31, 2013.
    Title VIII of the Food and Drug Administration Amendments Act of
2007 (FDAAA) (Pub. L. 110-85) amended the PHS Act by adding section
402(j). The provisions require additional information to be submitted
to the clinical trials data bank (ClinicalTrials.gov) \1\ previously
established by the National Institutes of Health/National Library of
Medicine, including expanded information on clinical trials and
information on the results of clinical trials. The provisions include
responsibilities for FDA as well as several amendments to the Federal
Food, Drug, and Cosmetic Act (the FD&C Act).
---------------------------------------------------------------------------

    \1\ FDA has verified the Web site address, but FDA is not
responsible for any subsequent changes to the Web site after this
document publishes in the Federal Register.
---------------------------------------------------------------------------

    One provision, section 402(j)(5)(B) of the PHS Act, requires that a
certification accompany human drug, biological, and device product
submissions made to FDA. Specifically, at the time of submission of an
application under sections 505, 515, or 520(m) of the FD&C Act (21
U.S.C. 355, 360e, or 360j(m)), or under section 351 of the PHS Act (42
U.S.C. 262), or submission of a report under section 510(k) of the FD&C
Act (21 U.S.C. 360(k)), such application or submission must be
accompanied by a certification, Form FDA 3674, that all applicable
requirements of section 402(j) of the PHS Act have been met. Where
available, such certification must include the appropriate National
Clinical Trial (NCT) numbers.
    The proposed extension of the collection of information is
necessary to satisfy the previously mentioned statutory requirement.
    The importance of obtaining these data relates to adherence to the
legal requirements for submissions to the clinical trials registry and
results data bank and ensuring that individuals and organizations
submitting applications or reports to FDA under the listed provisions
of the FD&C Act or the PHS Act adhere to the appropriate legal and
regulatory requirements for certifying to having complied with those
requirements. The failure to submit the certification required by
section 402(j)(5)(B) of the PHS Act, and the knowing submission of a
false certification are both prohibited acts under section 301 of the
FD&C Act (21 U.S.C. 331). Violations are subject to civil money
penalties.
    In January 2009, FDA issued ``Guidance for Sponsors, Industry,
Researchers, Investigators, and Food and Drug Administration Staff--
Certifications To Accompany Drug, Biological Product, and Device
Applications/Submissions: Compliance with Section 402(j) of The Public
Health Service Act, Added By Title VIII of The Food and Drug
Administration Amendments Act of 2007'' available at http://www.fda.gov/RegulatoryInformation/Guidances/ucm125335.htm. This
guidance identified the applications and submissions that FDA
considered should be accompanied by the certification form, Form FDA
3674. The applications and submissions noted in the guidance are
reflected in the burden analysis.

Investigational New Drug Applications

    FDA's Center for Drug Evaluation and Research (CDER) received 1,752
investigational new drug applications (INDs) and 11,769 clinical
protocol IND amendments in Fiscal Year (FY) 2010. CDER anticipates that
IND and clinical protocol amendment submission rates will remain at or
near this level in the near future.
    FDA's Center for Biologics Evaluation and Research (CBER) received
281 new INDs and 1,471 clinical protocol IND amendments in FY 2010.
CBER anticipates that IND and clinical protocol amendment submission
rates will remain at or near this level in the near future.
    The estimated total number of submissions (new INDs and new
protocol submissions) subject to mandatory certification requirements
under section 402(j)(5)(B) of the PHS Act, is 13,521 for CDER plus
1,752 for CBER, or 15,273 submissions per year. The minutes per
response is the estimated number of minutes that a respondent would
spend preparing the information to be submitted to FDA under section
402(j)(5)(B) of the PHS Act, including the time it takes to enter the
necessary information on the form.
    Based on its experience with current submissions, FDA estimates
that approximately 15.0 minutes on average would be needed per response
for certifications which accompany IND applications and clinical
protocol amendment submissions. It is assumed that most submissions to
investigational applications will reference only a few protocols for
which the sponsor/applicant/submitter has obtained a NCT number from
ClinicalTrials.gov prior to making the submission to FDA. It is also
assumed that the sponsor/applicant/submitter has electronic
capabilities allowing them to retrieve the information necessary to
complete the form in an efficient manner.

Marketing Applications/Submissions

    In 2010, CDER and CBER received 165 new drug applications (NDA)/
biologics license applications (BLA)/resubmissions and 1,483 NDA/BLA
amendments for which certifications are needed. CDER and CBER received
191 efficacy supplements/resubmissions to previously approved NDAs/BLAs
in FY 2010. CDER and CBER anticipate that new drug/biologic
applications/resubmissions and efficacy supplement submission rates
will remain at or near this level in the near future.
    FDA's Center for Devices and Radiological Health (CDRH) received a
total of 892 new applications for premarket approvals (PMA), 510(k)
submissions containing clinical information, PMA supplements,
applications for humanitarian device exemptions (HDE) and amendments,
for a total of 424 new applications/submissions in FY 2010. CDRH
anticipates that application, amendment, supplement, and annual report
submission rates will remain at or near this level in the near future.
    FDA's Office of Generic Drugs (OGD) received 854 abbreviated new
drug applications (ANDAs) in FY 2010. OGD received 495 bioequivalence
amendments/supplements FY 2010. OGD anticipates that application,
amendment, and supplement submission rates will remain at or near this
level in the near future.
    Based on its experience reviewing NDAs, BLAs, PMAs, HDEs, 510(k)s,
and ANDAs and experience with current submissions of Form FDA 3674, FDA
estimates that approximately 45.0 minutes on average would be needed
per response for certifications which accompany NDA, BLA, PMA, HDE,
510(k), and ANDA marketing applications and submissions. It is assumed
that the sponsor/applicant/submitter has electronic capabilities
allowing them to retrieve the information necessary to complete the
form in an efficient manner.

    FDA estimates the burden of this collection of information as
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            Number of        Number of                                        Average
                                                           respondents      respondents      Number of     Total annual     burden per
                  FDA Center Activity                   (investigational    (marketing     responses per     responses     response  (in    Total hours
                                                          applications)    applications)    respondent                      hours) \2\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CDER
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Applications (IND)................................            1,752   ..............               1           1,752           15/60             438
Clinical Protocol Amendments (IND)....................           11,769   ..............               1          11,769           15/60           2,943
New Marketing Applications/Resubmissions (NDA/BLA)....  ................             157               1             157           45/60             118
Clinical Amendments to Marketing Applications.........  ................           1,466               1           1,466           45/60           1,100
Efficacy Supplements/Resubmissions....................  ................             166               1             166           45/60             125
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CBER
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Applications (IND)................................              281   ..............               1             281           15/60              70
Clinical Protocol Amendments (IND)....................            1,471   ..............               1           1,471           15/60             368
New Marketing Applications/Resubmissions..............  ................               8               1               8           45/60               6
Clinical Amendments to Marketing Applications.........  ................              17               1              17           45/60              13
Efficacy Supplements/Resubmissions (BLA only).........  ................              25               1              25           45/60              19
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          CDRH
--------------------------------------------------------------------------------------------------------------------------------------------------------
New Marketing Applications (includes PMAs, HDEs,        ................             892               1             892           45/60             669
 Supplements and 510(k)s expected to contain clinical
 data)................................................
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           OGD
--------------------------------------------------------------------------------------------------------------------------------------------------------
Original Applications.................................  ................             854               1             854           45/60             641
BE Supplements/Amendments.............................  ................             495  ..............  ..............           45/60             372
                                                       -------------------------------------------------------------------------------------------------
    Total.............................................  ................  ..............  ..............  ..............  ..............           6,882
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capitol costs or operating and maintenance costs associated with this collection of information.
\2\ Burden estimates of less than 1 hour are expressed as a fraction of an hour in the format ``[number of minutes per response]/60''.

    Dated: May 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-11073 Filed 5-5-11; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 80, Number 39 (Friday, February 27, 2015)]
[Notices]
[Pages 10731-10732]
[FR Doc No: 2015-04064]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange
Commission, Office of FOIA Services, 100 F Street NE., Washington, DC
20549-2736.

Extension:
    Rule 17Ac2-2 and Form TA-2; SEC File No. 270-298, OMB Control
No. 3235-0337.

    Notice is hereby given that pursuant to the Paperwork Reduction Act
of 1995 (``PRA'') (44 U.S.C. 3501 et seq.), the Securities and Exchange
Commission (``Commission'') is soliciting comments on the existing
collection of information provided for in Rule 17Ac2-2 (17 CFR
240.17Ac2-2) and Form TA-2 under the Securities Exchange Act of 1934
(15 U.S.C. 78a et seq.) (``Exchange Act''). The Commission plans to
submit this existing collection of information to the

Office of Management and Budget (``OMB'') for extension and approval.
    Rule 17Ac2-2 and Form TA-2 require registered transfer agents to
file an annual report of their business activities with the Commission.
These reporting requirements are designed to ensure that all registered
transfer agents are providing the Commission with sufficient
information on an annual basis about the transfer agent community and
to permit the Commission to effectively monitor business activities of
transfer agents.
    The amount of time needed to comply with the requirements of
amended Rule 17Ac2-2 and Form TA-2 varies. Of the total 429 registered
transfer agents, approximately 9.1% (or 39 registrants) would be
required to complete only questions 1 through 3 and the signature
section of amended Form TA-2, which the Commission estimates would take
each registrant approximately 30 minutes, for a total burden of 19.5
hours (39 x .5 hours). Approximately 26.7% of registrants (or 115
registrants) would be required to answer questions 1 through 5,
question 11 and the signature section, which the Commission estimates
would take approximately 1 hour and 30 minutes, for a total of 172.5
hours (115 x 1.5 hours). Approximately 64.2% of the registrants (or 275
registrants) would be required to complete the entire Form TA-2, which
the Commission estimates would take approximately 6 hours, for a total
of 1,650 hours (275 x 6 hours). The aggregate annual burden on all 429
registered transfer agents is thus approximately 1,842 hours (19.5
hours + 172.5 hours + 1,650 hours) and the average annual burden per
transfer agent is approximately 4.3 hours (1,842 / 429).
    Written comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the Commission, including whether the information
shall have practical utility; (b) the accuracy of the Commission's
estimates of the burden of the proposed collection of information; (c)
ways to enhance the quality, utility, and clarity of the information on
respondents; and (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted in
writing within 60 days of this publication.
    An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information under the PRA unless it
displays a currently valid OMB control number.
    Please direct your written comments to: Pamela Dyson, Director/
Chief Information Officer, Securities and Exchange Commission, c/o Remi
Pavlik-Simon, 100 F Street NE., Washington, DC 20549, or send an email
to<EMAIL_ADDRESS>
    Dated: February 23, 2015.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2015-04064 Filed 2-26-15; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 78, Number 18 (Monday, January 28, 2013)]
[Notices]
[Pages 5800-5801]
[FR Doc No: 2013-01708]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[Docket ID Number EPA-HQ-OECA-2013-0042; FRL-9774-2]

Clean Water Act Class II: Proposed Administrative Settlement,
Penalty Assessment and Opportunity To Comment Regarding AboveNet
Communications, Inc.

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA has entered into a Consent Agreement with AboveNet
Communications, Inc. to resolve violations of the Clean Water Act (CWA)
and the Emergency Planning and Community Right-to-Know Act (EPCRA), and
their implementing regulations.
    The Administrator is hereby providing public notice of this Consent
Agreement and proposed Final Order (CAFO), and providing an opportunity
for interested persons to comment on the CWA and EPCRA portions of this
Consent Agreement, as required by CWA Section 311(b)(6)(C).

DATES: Comments are due on or before February 27, 2013.

ADDRESSES: Submit your comments, identified by Docket ID No. EPA-HQ-
OECA-2013-0042, by one of the following methods:
     www.regulations.gov: Follow the on-line instructions for
submitting comments.
     Email<EMAIL_ADDRESS>Attention Docket ID No. EPA-
HQ-OECA-2013-0042.
     Fax:<PHONE_NUMBER>, Attention Docket ID No. EPA-HQ-OECA-
2013-0042.
     Mail: Enforcement and Compliance Docket Information
Center, Environmental Protection Agency, Mailcode: 2822T, 1200
Pennsylvania Ave. NW., Washington, DC 20460, Attention Docket ID No.
EPA-HQ-OECA-2013-0042.
     Hand Delivery: Enforcement and Compliance Docket
Information Center in the EPA Docket Center (EPA/DC), EPA West, Room B
3334, 1301 Constitution Avenue NW., Washington, DC. The EPA Docket
Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday
through Friday, excluding legal holidays. The telephone number for the
Reading Room is<PHONE_NUMBER>, and the telephone number for the
Enforcement and Compliance Docket is<PHONE_NUMBER>. Such deliveries
are only accepted during the Docket's normal hours of operation, and
special arrangements should be made for deliveries of boxed
information.
    Instructions: Direct your comments to Docket ID No. EPA-HQ-OECA-
2013-0042. EPA's policy is that all comments received will be included
in the public docket without change and may be made available online at
www.regulations.gov, including any personal information provided,
unless the comment includes information claimed to be Confidential
Business Information (CBI) or other information whose disclosure is
restricted by statute. Do not submit information that you consider to
be CBI or otherwise protected through www.regulations.gov. The
www.regulations.gov Web site is an ``anonymous access'' system, which
means EPA will not know your identity or contact information unless you
provide it in the body of your comment. If you send an email comment
directly to EPA without going through www.regulations.gov, your email
address will be automatically captured and included as part of the
comment that is placed in the public docket and made available on the
Internet. If you submit an electronic comment, EPA recommends that you
include your name and other contact information in the body of your
comment and with any disk or CD-ROM you submit. If EPA cannot read your
comment due to technical difficulties and cannot contact you for
clarification, EPA may not be able to consider your comment. Electronic
files should avoid the use of special characters, any form of
encryption, and be free of any defects or viruses. For additional
information about EPA's public docket, visit the EPA Docket Center
homepage at http://www.epa.gov/epahome/dockets.htm.
    Docket: All documents in the docket are listed in the
www.regulations.gov index. Although listed in the index, some
information is not publicly available, e.g., CBI or other information
whose disclosure is restricted by statute. Certain other material, such
as copyrighted material, will be publicly available only in hard copy.
Publicly available docket materials are available either electronically
at www.regulations.gov or in hard copy at the Enforcement and
Compliance Docket Information Center in the EPA Docket Center (EPA/DC),
EPA West, Room B 3334, 1301 Constitution Avenue NW., Washington, DC.
The EPA Docket Center Public Reading Room is open from 8:30 a.m. to
4:30 p.m., Monday through Friday, excluding legal holidays. The
telephone number for the Reading Room is<PHONE_NUMBER>, and the
telephone number for the

Enforcement and Compliance Docket is<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Sanda Howland, Special Litigation and
Projects Division (2248-A), U.S. Environmental Protection Agency, 1200
Pennsylvania Avenue NW., Washington, DC 20460; telephone: (202) 564-
5022; fax:<PHONE_NUMBER>; email<EMAIL_ADDRESS>
I. Background

    This settlement agreement is the result of voluntary disclosures by
AboveNet Communications, Inc., (AboveNet) to the Special Litigation and
Projects Division (SLPD) in the Office of Civil Enforcement of
potential EPCRA Sections 311 and 312 reporting violations and CWA
violations related to Spill Prevention, Control, and Countermeasure
(SPCC) Plan requirements. AboveNet, a telecommunications company
organized under the laws of the state of Delaware and located at 360
Hamilton Avenue, White Plains, NY 10601, disclosed these potential
violations pursuant to EPA's Incentives for Self-Policing: Discovery,
Disclosure, Correction and Prevention of Violations (Audit Policy), 65
FR 19,618 (April 11, 2000).
    EPA determined that AboveNet's disclosures satisfied all the
conditions set forth in the Audit Policy, and therefore qualify for a
100% reduction of the civil penalty's gravity component. Pursuant to
the settlement agreement, EPA proposes to waive the gravity based
penalty. AboveNet will pay a civil penalty in the amount of $19,024.00,
which is the amount of the economic benefit gained by AboveNet
attributable to its delayed compliance with the CWA and EPCRA. EPA and
AboveNet negotiated an administrative Consent Agreement in accordance
with EPA's Consolidated Rules of Practice, 40 CFR part 22, specifically
40 CFR 22.13(b) and 22.18(b) (In the Matter of AboveNet Communications,
Inc., Docket Nos. CWA-HQ-2012-8000, EPCRA-HQ-2012-8000). This Consent
Agreement is subject to public notice and comment under CWA Section
311(b)(6)(C), 33 U.S.C. 1321(b)(6)(C).
    AboveNet violated CWA Section 311(j), 33 U.S.C. 1321(j), and the
regulations found at 40 CFR part 112, because it failed to prepare and
implement SPCC plans for the 4 facilities listed below. As authorized
by CWA Section 311(b)(6), 33 U.S.C. 1321(b)(6), EPA has assessed a
civil penalty for these violations.

----------------------------------------------------------------------------------------------------------------
                       Site/building code            Address                  City                  State
----------------------------------------------------------------------------------------------------------------
1..................  DC-21M................  2100 M Street NW.,      Washington............  DC.
                                              Suite P110.
2..................  IL-52R................  5201 Rose Street......  Chicago...............  IL.
3..................  MA-SUM................  1 Summer Street.......  Boston................  MA.
4..................  PA-401................  401 N. Broad Street,    Philadelphia..........  PA.
                                              Suites 240 & 323.
----------------------------------------------------------------------------------------------------------------

    Under CWA Section 311(b)(6)(A), 33 U.S.C. 1321(b)(6)(A), any owner,
operator, or person in charge of a vessel, onshore facility, or
offshore facility from which oil is discharged in violation of CWA
Section 311(b)(3), 33 U.S.C. 1321(b)(3), or who fails or refuses to
comply with any regulations that have been issued under CWA Section
311(j), 33 U.S.C. 1321(j), may be assessed an administrative civil
penalty of up to $177,500 by EPA. Class II proceedings under CWA
Section 311(b)(6) are conducted in accordance with 40 CFR part 22.
    AboveNet also violated EPCRA Section 311, 42 U.S.C. 11021, and the
regulations found at 40 CFR part 370, when it failed to submit a
Material Safety Data Sheet (MSDS) for a hazardous chemical(s) or, in
the alternative, a list of such chemicals, at 48 facilities for varying
lengths of time between 2007 and 2011. EPA, as authorized by EPCRA
Section 325, 42 U.S.C. 11045, has assessed a civil penalty for these
violations.
    AboveNet also violated EPCRA Section 312, 42 U.S.C. 11022, and the
regulations found at 40 CFR part 370, when it failed to prepare and
submit emergency and chemical inventory forms to the Local Emergency
Planning Commission (LEPC), the State Emergency Response Commission
(SERC), and/or the fire department with jurisdiction over 48 facilities
listed in Attachment A for varying lengths of time between 2007 and
2011. EPA, as authorized by EPCRA Section 325, 42 U.S.C. 11045, has
assessed a civil penalty for these violations. Attachment A to the
proposed CAFO lists the 48 telecommunications facilities in violation
of EPCRA Sections 311 and 312.
    Under EPCRA Section 325, 42 U.S.C. 11045, the Administrator may
issue an administrative order assessing a civil penalty against any
person who has violated applicable emergency planning or right-to-know
requirements, or any other requirement of EPCRA. Proceedings under
EPCRA Section 325 are conducted in accordance with 40 CFR part 22.
    The procedures by which the public may comment on a proposed Class
II penalty order, or participate in a CWA Class II penalty proceeding,
are set forth in 40 CFR 22.45. The deadline for submitting public
comment on this proposed final order is February 27, 2013. All comments
will be transferred to the Environmental Appeals Board (EAB) of EPA for
consideration. The powers and duties of the EAB are outlined in 40 CFR
22.4(a).
    Pursuant to CWA Section 311(b)(6)(C), 33 U.S.C. 1321(b)(6)(C), EPA
will not issue an order in this proceeding prior to the close of the
public comment period.

List of Subjects

    Environmental protection.

    Dated: December 14, 2012.
Andrew Stewart,
Acting Division Director, Special Litigation and Projects Division,
Office of Enforcement and Compliance Assurance.
[FR Doc. 2013-01708 Filed 1-25-13; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 78, Number 154 (Friday, August 9, 2013)]
[Rules and Regulations]
[Page 48609]
[FR Doc No: 2013-19356]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[Docket No. USCG-2013-0607]

Drawbridge Operation Regulation; Delaware River, NJ; Correction

AGENCY: Coast Guard, DHS.

ACTION: Notice of deviation from drawbridge regulation; correction.

-----------------------------------------------------------------------

SUMMARY: On July 15, 2013, the Coast Guard published a temporary
deviation entitled ``Drawbridge Operation Regulation; Delaware River,
NJ'' for the operating schedule that governs the bascule span of the
Tacony-Palmyra Bridge, across the Delaware River, between the townships
of Tacony, PA and Palmyra, NJ. The deviation cited incorrect vertical
clearances in the navigable channel. This notice corrects that error.

DATES: Effective August 9, 2013.

FOR FURTHER INFORMATION CONTACT: If you have questions on this
temporary deviation, call or email Terrance Knowles, Environmental
Protection Specialist, Coast Guard; telephone<PHONE_NUMBER>, email
<EMAIL_ADDRESS>If you have questions on viewing the
docket, call Barbara Hairston, Program Manager, Docket Operations, at
202-366-9826.

SUPPLEMENTARY INFORMATION: On July 15, 2013 (78 FR 42010), the Coast
Guard published a temporary deviation from the operating schedule that
governs the bascule span of the Tacony-Palmyra Bridge (Route 73),
across the Delaware River, mile 107.2, between the townships of Tacony,
PA and Palmyra, NJ. The deviation cited incorrect vertical clearances
in the navigable channel during the rehabilitation project. This notice
corrects that error. Subsequent to the publication of that notice, the
Coast Guard discovered that the two vertical clearances, 53 feet and 50
feet above mean high water (MHW), were incorrect.

Correction

    In the notice (FR Doc. USCG-2013-0607) published on July 15, 2013
(78 FR 42010), make the following corrections on page 42011. In the
SUPPLEMENTARY INFORMATION section, paragraph two, the vertical
clearance in the closed position to vessels is 50 feet above MHW (not
53 feet). And, the clearance may be reduced by approximately 3 feet to
47 (not 50 feet) above MHW.

    Dated: July 19, 2013.
Waverly W. Gregory, Jr.,
Bridge Program Manager, Fifth Coast Guard District.
[FR Doc. 2013-19356 Filed 8-8-13; 8:45 am]
BILLING CODE 9110-04-P


[Federal Register Volume 82, Number 90 (Thursday, May 11, 2017)]
[Notices]
[Pages 21996-22000]
[FR Doc No: 2017-09559]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2016-0699; FRL-9960-31]

Certain New Chemicals; Receipt and Status Information for
February 2017

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA is required under the Toxic Substances Control Act (TSCA)
to publish in the Federal Register a notice of receipt of a
premanufacture notice (PMN); an application for a test marketing
exemption (TME), both pending and/or expired; and a periodic status
report on any new chemicals under EPA review and the receipt of notices
of commencement (NOC) to manufacture those chemicals. This document
covers the period from February 1, 2017 to February 28, 2017.

DATES: Comments identified by the specific case number provided in this
document, must be received on or before June 12, 2017.

ADDRESSES: Submit your comments, identified by docket identification
(ID) number EPA-HQ-OPPT-2016-0699, and the specific PMN number or TME
number for the chemical related to your comment, by one of the
following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be Confidential Business
Information (CBI) or other information whose disclosure is restricted
by statute.
     Mail: Document Control Office (7407M), Office of Pollution
Prevention and Toxics (OPPT), Environmental Protection Agency, 1200
Pennsylvania Ave. NW., Washington, DC 20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html.
    Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: For technical information contact: Jim
Rahai, IMD 7407M, Office of Pollution Prevention and Toxics,
Environmental Protection Agency, 1200 Pennsylvania Ave. NW.,
Washington, DC 20460-0001; telephone number:<PHONE_NUMBER>; email
address<EMAIL_ADDRESS>    For general information contact: The TSCA-Hotline, ABVI-Goodwill,
422 South Clinton Ave., Rochester, NY 14620; telephone number: (202)
554-1404; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general. As such, the
Agency has not attempted to describe the specific entities that this
action may apply to. Although others may be affected, this action
applies directly to the submitters of the actions addressed in this
document.

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through
regulations.gov or email. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or

CD-ROM the specific information that is claimed as CBI. In addition to
one complete version of the comment that includes information claimed
as CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the public docket.
Information so marked will not be disclosed except in accordance with
procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When preparing and submitting
your comments, see the commenting tips at http://www.epa.gov/dockets/comments.html.

II. What action is the Agency taking?

    This document provides receipt and status reports, which cover the
period from February 1, 2017 to February 28, 2017, and consists of the
PMNs and TMEs both pending and/or expired, and the NOCs to manufacture
a new chemical that the Agency has received under TSCA section 5 during
this time period.

III. What is the Agency's authority for taking this action?

    Under TSCA, 15 U.S.C. 2601 et seq., EPA classifies a chemical
substance as either an ``existing'' chemical or a ``new'' chemical. Any
chemical substance that is not on EPA's TSCA Inventory is classified as
a ``new chemical,'' while those that are on the TSCA Inventory are
classified as an ``existing chemical.'' For more information about the
TSCA Inventory, please go to: http://www.epa.gov/opptintr/newchems/pubs/inventory.htm.
    Anyone who plans to manufacture or import a new chemical substance
for a non-exempt commercial purpose is required by TSCA section 5 to
provide EPA with a PMN, before initiating the activity. Section 5(h)(1)
of TSCA authorizes EPA to allow persons, upon application, to
manufacture (includes import) or process a new chemical substance, or a
chemical substance subject to a significant new use rule (SNUR) issued
under TSCA section 5(a), for ``test marketing'' purposes, which is
referred to as a test marketing exemption, or TME. For more information
about the requirements applicable to a new chemical go to: http://www.epa.gov/oppt/newchems.
    Under TSCA sections 5(d)(2) and 5(d)(3), EPA is required to publish
in the Federal Register a notice of receipt of a PMN or an application
for a TME and to publish in the Federal Register periodic reports on
the status of new chemicals under review and the receipt of NOCs to
manufacture those chemicals.

IV. Receipt and Status Reports

    As used in each of the tables in this unit, (S) indicates that the
information in the table is the specific information provided by the
submitter, and (G) indicates that the information in the table is
generic information because the specific information provided by the
submitter was claimed as CBI.
    For the 62 PMNs received by EPA during this period, Table 1
provides the following information (to the extent that such information
is not claimed as CBI): The EPA case number assigned to the PMN; The
date the PMN was received by EPA; the projected end date for EPA's
review of the PMN; the submitting manufacturer/importer; the potential
uses identified by the manufacturer/importer in the PMN; and the
chemical identity.

                        Table 1--PMNs Received From February 1, 2017 to February 28, 2017
----------------------------------------------------------------------------------------------------------------
                                         Projected
      Case No.         Received date    notice end       Manufacturer           Use               Chemical
                                           date            importer
----------------------------------------------------------------------------------------------------------------
P-17-0227...........        2/1/2017        5/2/2017  CBI..............  (G) Additive      (G) 2-alkenoic acid,
                                                                          open, non-        2-alkyl-, alkyl
                                                                          dispersive use.   ester, polymer with
                                                                                2-alkyl 2-propenoate
                                                                                and a-(2-alkyl-1-oxo-
                                                                                2-alken-1-yl-
                                                                                [iquest]-
                                                                                alkoxypoly(oxy-1,2-
                                                                                alkanediyl), ester
                                                                                with a-2-alken-1-yl-
                                                                                [iquest]-
                                                                                hydroxypoly(oxy-1,2-
                                                                                alkanediyl).
P-16-0186...........        2/6/2017        5/7/2017  CBI..............  (G) Surfactant..  (G) Sodium branched
                                                                                chain alkyl hydroxyl
                                                                                and branched chain
                                                                                alkenyl sulfonates.
P-16-0338...........       2/15/2017       5/16/2017  CBI..............  (G) Dyestuff....  (G) Xanthylium,
                                                                                (sulfoaryl)--bis
                                                                                [(substituted aryl)
                                                                                amino]-, sulfo
                                                                                derivs., inner
                                                                                salts, metal salts.
P-16-0339...........       2/15/2017       5/16/2017  CBI..............  (G) Dyestuff....  (G) Substituted
                                                                                triazinyl metal
                                                                                salt, diazotized,
                                                                                coupled with
                                                                                substituted
                                                                                pyridobenzimidazoles
                                                                                ulfonic acids,
                                                                                substituted
                                                                                pyridobenzimidazoles
                                                                                ulfonic acids,
                                                                                diazotized
                                                                                substituted
                                                                                alkanesulfonic acid,
                                                                                diazotized
                                                                                substituted aromatic
                                                                                sulfonate,
                                                                                diazotized
                                                                                substituted aromatic
                                                                                sulfonate, metal
                                                                                salts.
P-16-0358...........       2/17/2017       5/18/2017  CBI..............  (S) Chemical      (G) Alkyl phenol.
                                                                          intermediate.
P-16-0439...........       2/14/2017       5/15/2017  CBI..............  (G) Coloring      (G) Carbon black,
                                                                          agent.            (organic acidic
                                                                                carbocyclic)-
                                                                                modified, inorganic
                                                                                salt.
P-16-0440...........       2/14/2017       5/15/2017  CBI..............  (G) Coloring      (G) Carbon black,
                                                                          agent.            (organic acidic
                                                                                carbocyclic)-
                                                                                modified, metal
                                                                                salt.
P-16-0513...........        2/3/2017        5/4/2017  CBI..............  (S) Intermediate  (G) Hydroxy
                                                                          for further       alkylbiphenyl.
                                                                          reaction.
P-16-0514...........       2/28/2017       5/29/2017  CBI..............  (G) Catalyst....  (G) Mixed metal
                                                                                oxide.
P-16-0543...........       2/23/2017       5/24/2017  CBI..............  (G) Battery       (G)
                                                                          ingredient.       Halogenophosphoric
                                                                                acid metal salt.
P-16-0544...........        2/6/2017        5/7/2017  Guardian           (S) Additive to   (S) Flue dust, glass-
                                                       Industries Corp.   influence         manufg.
                                                                          melting           desulfurization,
                                                                          temperature of    calcium hydroxide-
                                                                          raw materials     treateddefinition:
                                                                          and physical      the dust produced
                                                                          characteristics   form the flue gas
                                                                          of the final      exhaust cleaning of
                                                                          product during    a glass
                                                                          the manufacture   manufacturing
                                                                          of flat glass.    process followed by
                                                                                treatment with
                                                                                hydrated lime. it
                                                                                consists primarily
                                                                                of caso4 and
                                                                                ca(co3).
P-16-0570...........       2/10/2017       5/11/2017  CBI..............  (S) Aromatic      (G) Aromatic
                                                                          polyester         polyester polyol.
                                                                          polyol for
                                                                          rigid foam.
P-16-0593...........       2/24/2017       5/25/2017  CBI..............  (S) Aromatic      (G) Aromatic
                                                                          polyester         polyester polyol.
                                                                          polyol for
                                                                          rigid foam.
P-16-0595...........       2/23/2017       5/24/2017  CBI..............  (G) Polymer.....  (G) Substituted-
                                                                                (hydroxyalkyl)-alkyl-
                                                                                alkanoic acid,
                                                                                hydroxy-
                                                                                (substitutedalkyl)-
                                                                                alkyl-, polymer with
                                                                                alpha-hydro-omega-
                                                                                hydroxypoly[oxy(alky
                                                                                l-ethanediyl)] and
                                                                                isocyanato-
                                                                                (isocyanatoalkyl)-
                                                                                multialkylcycloalkan
                                                                                e, salt, alkanol-
                                                                                blocked, compds.

P-16-0599...........       2/23/2017       5/24/2017  CBI..............  (G) Binder        (G) Benzoic acid, 4-
                                                                          resinopen non-    [(4-
                                                                          dispersive use.   ethenylphenyl)alkoxy
                                                                                ]-2-hydroxy-,
                                                                                polymer with
                                                                                ethenylbenzene and
                                                                                octadecyl 2-methyl-2-
                                                                                propenoate.
P-17-0014...........       2/10/2017       5/11/2017  Santolubes         (G) Gear          (S) Fatty acids, c8-
                                                       Manufacturing      lubricant.        c10, mixed esters
                                                       Llc.                                 with c18-unsatd.
                                                                                fatty acid dimers
                                                                                and alpha-hydro-
                                                                                omega-
                                                                                hydroxypoly(oxy-1,4-
                                                                                butanediyl).
P-17-0028...........       2/14/2017       5/15/2017  Henkel             (G) Component in  (S) Fatty acid,
                                                       Corporation.       a epoxy           castor oil, reaction
                                                                          encapsulant.      products with
                                                                                epichlorohydrin.
P-17-0117...........       2/14/2017       5/15/2017  CBI..............  (G) Use as a      (S) 1,6,10-
                                                                          polyol for        dodecatriene, 7,11-
                                                                          polyurethane      dimethyl-3-methylene-
                                                                          manufacture.      , (6e)-,
                                                                          reaction of the   homopolymer, 2-
                                                                          new substance     hydroxypropyl-
                                                                          with a            terminated.
                                                                          diisocyanate or
                                                                          Polyisocyanate
                                                                          And other
                                                                          polyols will
                                                                          produce a
                                                                          higher mw
                                                                          polymer.
P-17-0117...........       2/14/2017       5/15/2017  CBI..............  (S) Used as a     (S) 1,6,10-
                                                                          feedstock for     dodecatriene, 7,11-
                                                                          hydrogenation     dimethyl-3-methylene-
                                                                          to produce a      , (6e)-,
                                                                          saturated diol    homopolymer, 2-
                                                                          for use in        hydroxypropyl-
                                                                          urethane          terminated.
                                                                          chemistry or as
                                                                          an additive in
                                                                          coatings
                                                                          adhesives or
                                                                          sealants.
P-17-0118...........       2/14/2017       5/15/2017  CBI..............  (S) Used as a     (S) 1,6,10-
                                                                          feedstock for     dodecatriene, 7,11-
                                                                          hydrogenation     dimethyl-3-methylene-
                                                                          to produce a      , (6e)-,
                                                                          saturated diol    homopolymer, 2-
                                                                          for use in        hydroxyethyl-
                                                                          urethane          terminated.
                                                                          chemistry or as
                                                                          an additive in
                                                                          coatings,
                                                                          adhesives or
                                                                          sealants..
                                                                         (G) Use as a
                                                                          polyol for
                                                                          polyurethane
                                                                          manufacture.
                                                                          reaction of the
                                                                          new substance
                                                                          with a
                                                                          diisocyanate or
                                                                          polyisocyanate
                                                                          and other
                                                                          polyols will
                                                                          produce a
                                                                          higher mw
                                                                          polymer.
P-17-0149...........        2/6/2017        5/7/2017  CBI..............  (G) Electronic    (G) Fluorocyanophenyl
                                                                          use.              alkylbenzoate.
                                                                         (G) Electronic
                                                                          device use.
P-17-0168...........        2/7/2017        5/8/2017  CBI..............  (G) Surfactants.  (G) Fatty secondary
                                                                         (G) Intermediate   amide ethanol.
P-17-0169...........        2/7/2017        5/8/2017  CBI..............  (G) Surfactants.  (G) Fatty tertiary
                                                                         (G) Intermediate   amide ethanol.
P-17-0172...........       2/14/2017       5/15/2017  CBI..............  (G) Lubricating   (G) Sulfurized
                                                                          oil additive.     alkylphenol, calcium
                                                                                salts.
P-17-0176...........        2/6/2017        5/7/2017  CBI..............  (G) Battery       (G) Carbonic acid,
                                                                          ingredient.       alkyl
                                                                                carbomonocyclic
                                                                                ester.
P-17-0177...........       2/25/2017       5/26/2017  Shin-Etsu Microsi  (G)               (G)
                                                                          Microlithograph   Monoheteropentacyclo
                                                                          y for             alkane-4-carboxylic
                                                                          electronic        acid, substituted-
                                                                          device            cycloalkyl ester.
                                                                          manufacturing.
P-17-0178...........       2/25/2017       5/26/2017  Shin-Etsu Microsi  (G)               (G) Sulfonium,
                                                                          Microlithograph   triphenyl-, salt
                                                                          y for             with substituted-
                                                                          electronic        alkyl 4-substituted-
                                                                          device            benzoate.
                                                                          manufacturing.
P-17-0188...........       2/14/2017       5/15/2017  CBI..............  (G) Binder resin  (G) Alpha-omega,
                                                                          for adhesives/    silane-terminated,
                                                                          sealants.         polyether polyol
                                                                                based polyurethane
                                                                                polymer.
P-17-0189...........        2/8/2017        5/9/2017  Double Bond        (S)               (G)
                                                       Chemical           Doublemer[supre   Polyhalogenatedbicyc
                                                       Industries Usa,    g]278-X25 is a    loalkenedicarboxylic
                                                       Inc.               ester acrylate    acid,
                                                                          monomer blended   methyl[oxyalkenyl)]e
                                                                          with 25%          thyl ester.
                                                                          isobornyl
                                                                          methacrylate,
                                                                          which improves
                                                                          adhesion to
                                                                          substrates,
                                                                          such as pp and
                                                                          pe, pet.
P-17-0199...........        2/3/2017        5/4/2017  CBI..............  (S) Binder in     (G) Oxyalkylene
                                                                          sealant.          urethane polyolefin.
P-17-0208...........        2/5/2017        5/6/2017  Alberdingk Boley   (S) Coating for   (G) Alkanoic acid,
                                                       Inc.               leather and       hydroxy(hydroxymethy
                                                                          plastic.          l)-alkyl-, polymer
                                                                         (S) Coating for    with
                                                                          plastics and      diisocyanatoalkane,
                                                                          metal.            dialkyl carbonate,
                                                                                aldanediol, .alpha.-
                                                                                hydro-.omega.-
                                                                                hydroxypoly(oxyalkan
                                                                                ediyl), 1,1'-
                                                                                alkylenebis[isocyana
                                                                                tocycloalkane] and a
                                                                                lactone.
P-17-0209...........        2/5/2017        5/6/2017  Alberdingk Boley   (S) Coating for   (G) Alkanoic acid, x-
                                                       Inc.               plastic and       hydroxy-y-
                                                                          metal.            (hydroxyalkyl)-y-
                                                                         (S) Coating for    alkyl-, polymer with
                                                                          leather and       dialkyl carbonate,
                                                                          plastic.          alkanediol,
                                                                                alkylenebis
                                                                                [isocyanatocycloalka
                                                                                ne] and lactone,
                                                                                compd. with trialkyl
                                                                                amine.
P-17-0210...........        2/5/2017        5/6/2017  Alberdingk Boley   (S) Coating for   (G) Alkanoic acid, x-
                                                       Inc.               plastics and      hydroxy-y-
                                                                          metal.            (hydroxyalkyl)-x-
                                                                         (S) Coating for    alkyl-, polymer with
                                                                          leather and       dialkyl carbonate,
                                                                          plastic.          alkanediol,
                                                                                isocyanato-1-
                                                                                (isocyanatoalkyl)-
                                                                                trialkylcycloalkane,
                                                                                alkylenebis[isocyana
                                                                                tocycloalkane] and
                                                                                lactone,
                                                                                polyethylene glycon
                                                                                mono me ether-
                                                                                blocked, compds.
                                                                                with trialkyl amine.
P-17-0211...........        2/5/2017        5/6/2017  Alberdingk Boley   (S) Coating for   (G) Alkanoic acid, x-
                                                       Inc.               leather and       hydroxy-y-
                                                                          plastic.          (hydroxyalkyl)-y-
                                                                         (S) Coating for    alkyl-, polymer with
                                                                          plastics and      dialkyl carbonate,
                                                                          metal.            alkanediol,
                                                                                alkylenebis[iscyanat
                                                                                ocycloalkane] and
                                                                                lactone, compd. with
                                                                                trialkylamine.
P-17-0216...........       2/28/2017       5/29/2017  CBI..............  (G) Paint raw     (G) Acryl-modified
                                                                          material.         epoxy polymer with
                                                                                vegitable oil, fatty
                                                                                acid, acrylates and
                                                                                methacyrlates with
                                                                                organic amine.

P-17-0217...........       2/14/2017       5/15/2017  Ngk Ceramics Usa,  (S) Additive to   (S) Coke, (coal),
                                                       Inc.               diesel            secondary pitch.
                                                                          particulate
                                                                          filter
                                                                          manufacture.
                                                                          this material
                                                                          is added to the
                                                                          clay prior to
                                                                          forming into a
                                                                          substrate. when
                                                                          the substrate
                                                                          is fired in a
                                                                          kiln, the
                                                                          material burns
                                                                          out, leaving
                                                                          internal pores.
                                                                          these pores
                                                                          collect the
                                                                          emission soot
                                                                          during the
                                                                          operation of
                                                                          the dpf after
                                                                          being installed
                                                                          on the vehicle.
P-17-0226...........        2/2/2017        5/3/2017  Nease Corporation  (G) Bleach        (S) Manganese(2+ ),
                                                                          catalyst.         bis(octahydro-1,4,7-
                                                                                trimethyl-1h-1,4,7-
                                                                                triazonine-
                                                                                [iquest]n1,[iquest]n
                                                                                4,.kappa.n7)tri-[mu]-
                                                                                oxodi-
                                                                                ,hexafluorophosphate
                                                                                (1-) (1:2).
P-17-0228...........        2/2/2017        5/3/2017  CBI..............  (G) Coating for   (G) 2'-fluoro-4''-
                                                                          displays.         alkyl-4-propyl-
                                                                                1,1':4',1''-
                                                                                terphenyl.
P-17-0229...........        2/2/2017        5/3/2017  CBI..............  (G) Coating for   (G) 4-ethyl-2'-fluoro-
                                                                          displays.         4''-alkyl-
                                                                                1,1':4',1''-
                                                                                terphenyl.
P-17-0230...........        2/3/2017        5/4/2017  CBI..............  (G) Additive,     (G) Oxirane, 2-alkyl-
                                                                          open, non-        , polymer with
                                                                          dispersive use.   oxirane, mono[n-[3-
                                                                                (carboxyamino)-4(or
                                                                                6)-
                                                                                alkylphenyl]carbamat
                                                                                e], alkyl ether,
                                                                                ester with 2,2',2''-
                                                                                nitrilotris-
                                                                                [alkanol].
P-17-0231...........        2/6/2017        5/7/2017  CBI..............  (G) Paint, stain  (G) Fatty acids,
                                                                          or primer         polymers with
                                                                          coating.          benzoic acid,
                                                                                cyclohexanedicarboxy
                                                                                lic acid anhydride,
                                                                                aliphatic
                                                                                diisocyanate, alkyl
                                                                                diol, alkyl triol,
                                                                                pentaerythritol,
                                                                                phthalic anhydride,
                                                                                polyalkylene glycol
                                                                                amine, and aromatic
                                                                                dicarboxylate
                                                                                sulphonic acid
                                                                                sodium salt.
P-17-0233...........       2/10/2017       5/11/2017  CBI..............  (S) Creping aid   (G) Oxyalkylene
                                                                          for yankee        modified polyalkyl
                                                                          dryers to         amine alkyl diacid
                                                                          manufacture       polymer with 2-
                                                                          tissue and        (chloromethyl)oxiran
                                                                          towel paper.      e.
P-17-0234...........       2/12/2017       5/13/2017  CBI..............  (S) Adhesive      (S) Oxirane, 2-
                                                                          intermediate.     (chloromethyl)-,
                                                                                polymer with 2-
                                                                                methyloxirane
                                                                                polymer with oxirane
                                                                                bis(2-aminopropyl)
                                                                                ether.
P-17-0235...........       2/10/2017       5/11/2017  CBI..............  (G) Anti-         (G) Amidoamino
                                                                          agglomerate.      quaternary ammonium
                                                                                salt.
P-17-0236...........       2/23/2017       5/24/2017  CBI..............  (G) Matrix resin  (G) Formaldehyde,
                                                                          for composite     polymer with
                                                                          materials.        (chloromethyl)
                                                                         (G) Binder resin   oxirane and
                                                                          for electronic    substituted aromatic
                                                                          materials.        compounds.
P-17-0237...........       2/23/2017       5/24/2017  CBI..............  (S) Loca (see     (S) 1,6,10-
                                                                          description for   dodecatriene, 7,11-
                                                                          the primary       dimethyl-3-methylene-
                                                                          diol). due to     , (6e)-,
                                                                          its lower         homopolymer,
                                                                          reactivity,       hydrogenated, 2-
                                                                          very little of    hydroxyethyl-
                                                                          the               terminated.
                                                                          hydrogenated
                                                                          secondary diol
                                                                          will be made or
                                                                          sold for this
                                                                          use. the uses
                                                                          would be
                                                                          identical to
                                                                          the use of the
                                                                          hydrogenated
                                                                          primary diol.
                                                                         (G) Export
                                                                          overseas for
                                                                          use in
                                                                          polyurethanes.
                                                                         (G) Use in uv
                                                                          cured systems.
P-17-0238...........       2/23/2017       5/24/2017  CBI..............  (S) Loca (see     (S) 1,6,10-
                                                                          description for   dodecatriene, 7,11-
                                                                          the primary       dimethyl-3-methylene-
                                                                          diol). due to     , (6e)-,
                                                                          its lower         homopolymer, 2-
                                                                          reactivity,       hydroxypropyl-
                                                                          very little of    terminated,
                                                                          the               hydrogenated.
                                                                          hydrogenated
                                                                          secondary diol
                                                                          will be made or
                                                                          sold for this
                                                                          use. the uses
                                                                          would be
                                                                          identical to
                                                                          the use of the
                                                                          hydrogenated
                                                                          primary diol.
                                                                         (G) For use as a
                                                                          plasticizer in
                                                                          uv cure
                                                                          formulations.
                                                                         (G) Export
                                                                          overseas for
                                                                          use in
                                                                          polyurethanes.
                                                                         (G) Use in uv
                                                                          cured systems.
P-17-0246...........       2/28/2017       5/29/2017  CBI..............  (G) Industrial    (G) Polycarbonate
                                                                          intermediate.     polyol.
----------------------------------------------------------------------------------------------------------------

    For the 12 NOCs received by EPA during this period, Table 2
provides the following information (to the extent that such information
is not claimed as CBI): The EPA case number assigned to the NOC; the
date the NOC was received by EPA; the projected date of commencement
provided by the submitter in the NOC; and the chemical identity.

                        Table 2--NOCs Received From February 1, 2017 to February 28, 2017
----------------------------------------------------------------------------------------------------------------
               Case No.                 Received date  Commencement date                 Chemical
----------------------------------------------------------------------------------------------------------------
J-16-0023............................       2/10/2017          1/13/2017  (G) Trichoderma reesei modified.
P-13-0824............................        2/2/2017          1/19/2017  (S) D-glucitol, 1,4:3,6-dianhydro-,
                                                                           polymer with 1,4-
                                                                           cyclohexanedimethanol and diphenyl
                                                                           carbonate.
P-14-0166............................       2/23/2017          12/6/2016  (G) Fatty acid amide.
P-14-0185............................       2/23/2017          12/9/2016  (G) Fatty acid amide acetate.
P-14-0321............................        2/1/2017          1/11/2017  (S) 2-chloro-1,1,1,2-
                                                                           tetrafluoropropane(244bb).
P-15-0009............................        2/2/2017          1/29/2017  (S) Cyclohexane, 2-ethoxy-1,3-dimethyl-
                                                                           .
P-15-0751............................       2/10/2017          2/10/2017  (G) Naturally-occurring minerals,
                                                                           reaction products with hetero
                                                                           substituted alkyl acrylate polymer,
                                                                           kaolin and sodium silicate.
P-16-0177............................        2/2/2017          12/6/2016  (S) Barium molybdenum niobium tantalum
                                                                           tellurium vanadium zinc oxide.
P-16-0284............................       2/12/2017          1/24/2017  (G) ``anilino substituted bis-
                                                                           triazinyl derivative of 4, 4'-
                                                                           diaminostilbene-2, 2' disulfonic
                                                                           acid, mixed amine sodium salt''.
P-16-0367............................        2/2/2017           2/1/2017  (G) Substituted heteromonocycle,
                                                                           polymer with substituted alkane and
                                                                           ethoxylated alkane, substituted
                                                                           heteromonocycle substituted alkyl
                                                                           ester-blocked.
P-16-0369............................        2/2/2017           2/2/2017  (G) Substituted heteromonocycle,
                                                                           telomer with substituted
                                                                           carbomonocycles, substituted alkyl
                                                                           ester.
P-17-0144............................       2/21/2017          2/17/2017  (S) Amines, c36-alkylenedi-,polymers
                                                                           with octahydro-4,7-methano-1h-
                                                                           indenedimethanamine and pyromellitic
                                                                           dianhydride, maleated.
----------------------------------------------------------------------------------------------------------------

    Authority: 15 U.S.C. 2601 et seq.

    Dated: March 28, 2017.
Pamela Myrick,
Director, Information Management Division, Office of Pollution
Prevention and Toxics.
[FR Doc. 2017-09559 Filed 5-10-17; 8:45 am]
 BILLING CODE 6560-50-P


Comment Info: =================

General Comment:Dear Mr. Zeller:

I am writing as an individual consumer to request an extension of the comment period for the Food and Drug Administration's ("FDA") Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.

The Proposed Rule raises a number of significant issues and questions that are important and relevant to me, as a consumer of products that are proposed for regulation under the Proposed Rule. The Proposed Rule asks numerous questions I might potentially want to respond to. I want ample opportunity to provide my thoughts and comments on many of these issues should I decide to do so, but my time to devote to researching and providing thoughtful comments on these important questions is limited. I have already spent many hours researching these issues, but they take time. I know that the FDA took years to come up with the Proposed Rule, so I don't think it is unreasonable to allow us six months to comment on it. This is our only opportunity, as consumers, to provide our feedback.

I feel very strongly about e-cigarettes as an alternative to combustible cigarettes. Quite simply, I firmly believe that they saved my life. With all the different products available that are "approved" to aid in quitting smoking, I still wasn't able to find one that worked for me. However, e-cigarettes worked and I no longer smoke. I wish to provide you with my personal story, as well as science- and evidence-based responses to your questions so that you can take my comment into account. I realize that the FDA has the authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here, so that all stakeholders have the opportunity to provide their comments on this proposed regulation.

I appreciate your consideration of my request.